Huron Consulting Group Inc. will be added to the S&P SmallCap 600 index, replacing Supernus Pharmaceuticals Inc. due to its acquisition. This inclusion typically leads to increased institutional buying and liquidity for HURN shares, while SUPN's index position will be retained by the acquiring entity, Supernus Inc.
Huron Consulting Group's inclusion in the S&P SmallCap 600 is a positive development for the company. Index inclusion often leads to increased demand for a stock as passive funds tracking the index are required to purchase shares, potentially boosting liquidity and price. Supernus Pharmaceuticals is being acquired by Indivior Pharmaceuticals, which is the reason for its replacement; however, the combined entity, Supernus Inc., will retain its position in the index, making the impact on SUPN's index status neutral. For traders, this presents a short-term opportunity for HURN due to index-driven buying, while SUPN's trading will be more influenced by the merger terms. The long-term implications for HURN include enhanced visibility and potentially a lower cost of capital.